AUTHOR INDEX

Volume 38

July to December 1988

Abercrombie, B.A., 19
Albuquerque, E.G., 525
Albuquerque, L.A., 525
Allonen, H., 333
Aly, M.Y., 697
Andrade, A.T.L., 1
Arosemena, J.M., 631
Bamji, M.S., 91
Barker, D., 499
Barthlow, D., 525
Batten, B.E., 365
Baulieu, E-E, 675
Behlilovic, B., 631
Belsey, E. M., 1, 129, 181, 207, 227, 243
Bender, H.S., 585
Besch, P., 407
Birgerson, L., 391
Bisset, L.R., 567, 573
Boeckx, W., 99
Brandeis, A., 53, 465
Brosens, I., 99
Burns, J.W., 349
Busca, B., 165
Campbell, M.J., 165
Cardenas, H., 509
Carlson, N., 243
Casado, M.E., 37, 53
Cattanach, J.F., 541
Champion, C.B., 631
Chen, C-R, 641
Christensen, N.J., 301
Cole, L.P., 631
Cooke, I.D., 401
Croxatto, H.B., 37, 53, 465, 509
d'Arcangues, C., 165, 243, 259
de Leon-Medina, J.D., 551
de los Angeles Wens, M., 373
del Pino, G., 37
Diaz, S., 37, 53, 465, 509
Dockery, P., 401
Doody, M.C., 407
Drayer, D.E., 579
Du, M., 641
Dubois, C., 675
Ellingson, A.B., 27
Estrada, A.V., 373
Fan, H., 675
Farley, T.M.M., 129, 165
Fathalla, M.F., 697
Fazleabas, A.T., 349
Frohlich, J., 19
Gallegos, A.J., 373
Gao, J., 675
Gao, Y-L, 641
Garcia-Pineda, J., 373
Gibbons, W.E., 407
Goldzieher, J.W., 407
Gonzales-Olguin, A., 551
Gray, R., 499
Griffin, J.F.T., 567, 573
Grossman, R.A., 561
Gu, S., 641
Hahn, D.W., 109
Han, Z-B, 675
Haspels, A.A., 711
He, X., 641
Heap, R.B., 109
Heidt, F., 381, 477, 593
Heijnen, H.F.G., 711
Helm, P., 69
Herreros, C., 53
Holland, M.K., 685
Indian Council of Medical Research Task Force on Hormonal Contraception, 659
Johansson, E.D.B., 509
Jones, W.N., 19
Jung-Hoffmann, C., 381, 477, 593
Kaminski, J.M., 487
Kim, M.H., 365
Kjaeldgaard, A., 341
Kloosterboer, H.J., 325
Koh, S., 313, 441
Kotlik, A., 27
Kuhl, 381, 477, 593
Labbok, M., 499
Lai, S., 287
Larsson, B., 341
Larsson, M., 509
Lenton, E.A., 401

Li, T.C., 401
Lidegaard, Ø., 69
Liew, D., 79, 419, 453
Lindhe, B-Å, 341
Liu, Y-L, 641
Liu, Y.P., 641
Machin, D., 157, 165, 259
Mack, S.R., 487
Malacara, J.M., 551
Marshall, G., 37
McGuire, J., 109
Meng, U., 675
Miller, I.F., 349, 487
Milne, B.J., 541
Miranda, P., 53
Misra, H.P., 585
Mo, P., 641
Moreno, J.E., 407
Mullee, M.A., 259
Murray, P., 287
Odlind, V., 391
Pavez, M., 465, 509
Pedrón, N., 373
Peralta, O., 53
Percival-Smith, R.K.L., 19
Peregoudov, S., 227
Perez, A., 499
Phillips, A., 109
Pinol, A., 157
Pizarro, E., 1
Ponce-Monter, H., 373
Pschera, H., 341
Qi, L-F, 641
Qiao, G-M, 675
Quigg, J.M., 487
Rademakers, L.H.P.M., 711
Rådestad, A., 301
Ramalakshmi, B.A., 91
Randic, L., 631
Ratnam, S.S., 79, 313, 429, 441, 453
Ratsula, K., 333
Reidenberg, M.M., 579
Rider, V., 109
Rodríguez, G., 37, 53
Rogers, A.W., 401
Roh, S.I., 365
Romero-Gutiérrez, G., 551
Rowan, A.J., 525
Rowe, P.J., 1
Rubens, R., 419
Salah, M., 697
Salem, H.T., 697
Salvatierra, A.M., 53
Saunders, G.K., 585
Saxena, S.J., 487
Schiappacasse, V., 37
Schlesselman, J.J., 287
Shaaban, M.M., 697
Shaw, S.T., 1
Singh, K., 79, 313, 429, 441, 453
Singh, P., 79, 313, 429, 441, 453
Sivin, I., 641
Souza, J.P., 1
Spellacy, W.N., 27
Stadel, B.V., 287
Strömberg, L., 301
Taussig, M.J., 109
Thabet, A.I., 697
Toivonen, J., 333
Tsibris, J.C.M., 27
Turpijn, E.W., 325
Ulmann, A., 675
Van Santen, M.R., 711
Vercruysse, Ph., 99
Vermeulen, A., 419
Viegas, O.A.C., 79, 313, 429, 441, 453
Vijayalakshmi, R., 91
Vonk-Noordegraaf, C.A., 325
Wang, M.-W., 109
Wang, P-Z, 641
Wang, S.H., 641
Waszak, C.S., 525
Weitzman, G.A., 407
White, I.G., 685
Wilkens, L.R., 631
World Health Organization Task Force on Long-Acting Systemic Agents for Fertility Regulation, 181, 207, 227, 243
World Health Organization Task Force on Oral Contraceptives, 605
Wu, M-E, 675
Wu, S.L., 641
Wu, Y-M, 675
Xu, M.F., 641
Yao, G-Z, 675
Yuan, Y.D., 641
Zaneveld, L.J.D., 349, 487
Zhang, L.D., 641
Zheng, S-R, 675

SUBJECT INDEX

Volume 38

July-December, 1988

Acceptability,
  injectable contraceptives, 697
  levonorgestrel implants, 641
Anaerobic glycolysis, effect of ethinyl estradiol + d-norgestrel, 91
Analysis of menstrual bleeding patterns, a review, 219
Analysis of vaginal bleeding patterns, assessing changes, 165
Androgen levels, effect of ethinylestradiol + cyproterone acetate, 419
Androgen receptor binding, progestational compounds, 325
Anti-progesterone antibody, effect during pregnancy (rat), 109
Antifibrinolytic activity, effect of MSGB, 349
Bibliography of statistical analysis, vaginal bleeding patterns, 259
Bleeding pattern,
  effect of ethinyl estradiol + norethindrone, 525
  effect of levonorgestrel, 333, 659
Bleeding pattern indices, selection in analysis of menstrual bleeding patterns, 129
Blood pressure,
  effect of depot-medroxyprogesterone acetate, 697
  effect of levonorgestrel, 429, 659
  effect of norethisterone enanthate, 697
Body weight,
  effect of gossypol (rat), 585
  effect of levonorgestrel, 659
Breast cancer and oral contraceptive use, 287
Breastfeeding,
  effect on recovery of ovulation and fertility, 53
  use-effectiveness of Ovulation Method, 499
Breastfeeding pattern, effect on lactational amenorrhea, 37
Carbohydrate metabolism,
  effect of ethinyl estradiol + levonorgestrel, 27
  summary of data in literature on effect of triphasic oral contraceptives containing ethinyl estradiol + norgestrel, 27
2'-Carbomethoxyphenyl 4-guanidinobenzoate (MSGB),
  antifibrinolytic activity, 349
  contraceptive effect (rabbit), 349
Cervical mucus, influence of copper IUD on composition, 341
Cervix, effect of RU 486 for early pregnancy termination, 301
Changes in vaginal bleeding patterns during contraceptive use, methods of analysis, 165
Characteristics of contraceptive users, relationship to menstrual bleeding patterns, 243

Clearance of levonorgestrel, after removal of implants, 509
Clinical effects,
    effect of ethinylestradiol + desogestrel, 593
    effect of ethinylestradiol + gestodene, 593
    gossypol (rat), 585
Clinical experience, levonorgestrel, 429
Clinical trial,
    ethinyl estradiol + norethindrone, 525
    Multiload Cu 375, 631
    TCu 380Ag, 631
Clip technique sterilization, microsurgical reversal, 99
Coagulation factors, effect of levonorgestrel, 313, 441
Coagulation inhibitors, effect of levonorgestrel, 313, 441
Contraceptive discontinuation, relationship to vaginal bleeding patterns, 207
Contraceptive effect, MSBG (rabbit), 349
Contraceptive use,
    analysis of vaginal bleeding patterns, 181
    association between vaginal bleeding patterns and discontinuation, 207
    correlation with socioeconomic factors and personality profiles, 551
    menstrual bleeding patterns and influence of individual characteristics, 243
    menstrual bleeding patterns in relation to regional variations, 227
Contragestational effect, RU 486 (mouse), 365
Copper ions, effect on spermatozoa, 685
Copper IUD, influence on cervical mucus, 341
Copper-7, consequences of uterine blood loss, 1
Copper T 200, effect on estradiol level, 465
CUE™ Monitor, ovulation predictor for natural family planning, 407
CuT220c, effect on lipid metabolism, 605
Definitions and unit of analysis, use in analysis of menstrual bleeding pattern, 129
Dehydroepiandrosterone-sulphate level,
    effect of ethinylestradiol + desogestrel, 593
    effect of ethinylestradiol + gestodene, 593
Depot-medroxyprogesterone acetate,
    acceptability
    analysis of vaginal bleeding patterns, 181
    assessing changes in vaginal bleeding patterns, 165
    bleeding pattern, 207
    discontinuation, 207
    regional variations in bleeding patterns, 227
    subject characteristics in relation to bleeding patterns, 243
Dilatation of cervical canal, effect of RU 486, 301
Discontinuation of contraceptive use, relationship to vaginal bleeding patterns, 207

Discontinuations,
use of depot-medroxyprogesterone acetate, 697
use of ethinyl estradiol + norethindrone, 525
use of levonorgestrel, 641, 659
use of norethisterone enanthate, 697
Effectiveness, use of levonorgestrel, 641
Endometrium,
effect of ethinylestradiol, 711
effect of RU 486, 401
Estradiol level,
effect of copper T 200, 465
effect of ethinylestradiol + desogestrel, 593
effect of ethinylestradiol + gestodene, 593
effect of levonorgestrel, 465
effect of RU 486, 391
Estrogen in oral contraceptives, survey of prescribing habits for high-dose pills, 561
Estrous cycle, effect of gossypol (rat), 585
Ethinylestradiol, effect on endometrium, 711
Ethinylestradiol + cyproterone acetate, effect on androgens and lipids in hirsute or acneic women, 419
Ethinylestradiol + desogestrel,
clinical effects, 593
effect on hormone parameters, 593
levels of 3-keto-desogestrel and SHBG, 381
Ethinyl estradiol + ethynodiol diacetate, relative risk of premenopausal breast cancer in nulliparous women, 287
Ethinylestradiol + gestodene,
clinical effects, 593
effect on hormone parameters, 593
effect on serum levels of gestodene and SHBG, 477
Ethinyl estradiol + levonorgestrel,
analysis of vaginal bleeding patterns, 181
bleeding pattern, 207
discontinuations, 207
effect on carbohydrate metabolism, 27
effect on immunoglobulin levels, 567
effect on immunoglobulin production, 573
effect on lipid metabolism, 605
regional variations in bleeding patterns, 227
subject characteristics in relation to bleeding patterns, 243
Ethinyl estradiol + norethindrone,
clinical trial, 525
effect on lipid and lipoprotein levels, 19
Ethinylestradiol + norethisterone acetate,
analysis of vaginal bleeding patterns, 181
bleeding pattern, 207
discontinuations, 207
effect on lipid metabolism, 605
regional variations in bleeding patterns, 227
subject characteristics in relation to bleeding patterns, 243

Ethinyl estradiol + d-norgestrel, effect on glucose tolerance, 91
Ethinylestradiol + dl-norgestrel, effect on lipid and lipoprotein levels, 19
Ethylene-vinyl acetate copolymer, polymeric delivery system, 349
Falope ring sterilization, microsurgical reversal, 99
Fatty acid composition of cervical mucus lecithin, effect of copper IUD, 341
Ferritin level,
effect of IUD use, 1
effect of levonorgestrel, 333
Fertility, effect of breastfeeding, 53
Fertilization, effect of MSGB (rabbit), 349
Fibrinolytic activity, effect of levonorgestrel, 313, 441
FSH (follicle stimulating hormone)
FSH level,
effect of ethinylestradiol + desogestrel, 593
effect of ethinylestradiol + gestodene, 593
Gestodene, binding affinity for progesterone and androgen receptors, 325
Gestodene level, after administration of ethinylestradiol + gestodene, 477
Glucose tolerance test,
effect of ethinyl estradiol + levonorgestrel, 27
effect of levonorgestrel, 79, 453
Glycolytic metabolite levels, effect of ethinyl estradiol + d-norgestrel, 91
Gossypol,
effect on estrous cycles (rat), 585
effect on Na^+,K^+ ATPase activity, 579
histopathologic study (rat), 585
Haemoglobin level,
effect of IUD use, 1
effect of levonorgestrel, 333, 641
effect of RU 486 + dl-15-methyl-prostaglandin-$F_{2\alpha}$-methyl ester, 675
Haemostatic parameters, effect of levonorgestrel, 313, 441
hCG (human chorionic gonadotropin)
hCG level, effect of RU 486, 391
High-estrogen oral contraceptives, survey of prescribing habits, 561
Hirsute or acneic women, effect of ethinylestradiol + cyproterone acetate, 419
Histopathologic study, gossypol (rat), 585
Immune system, effect of oral contraceptives, 567, 573
Immunoglobin levels, effect of ethinyloestradiol + levonorgestrel, 567
Immunoglobulin production, effect of ethinyloestradiol + levonorgestrel, 573
Implant contraceptive, levonorgestrel, 79, 313, 429, 441, 453, 465, 509, 641, 659

Implantation,
effect of monoclonal antibody against progesterone (rat), 109
effect of MSGB (rabbit), 349
Injectable contraceptive,
depot-medroxyprogesterone acetate, 165, 181, 207, 227, 243, 697
norethisterone enanthate, 697
Insulin level, effect of ethinyl estradiol + levonorgestrel, 27
Intracervical device, releasing levonorgestrel, 333
Intrauterine device (IUD),
copper-7, 1
copper-T, 341
copper T 200, 465
CuT220c, 605
Lippes loop, 1
Multiload, 341
Multiload-250, 1
Multiload-375, 1, 631
progesterone-releasing, 1
T-Chloroquin, 1
TCu 200, 1
TCu 380Ag, 631
Iron status, effect of IUD use, 1
IUD (intrauterine device)
3-Keto-desogestrel (Org 3236), binding affinity for progesterone and androgen receptors, 325
3-Keto-desogestrel level, effect of ethinylestradiol + desogestrel, 381
Lactational amenorrhea, effect of breastfeeding pattern, 37
Lactational amenorrhea and recovery of ovulation and fertility, 53
Levonorgestrel,
analysis of vaginal bleeding patterns, 181
binding affinity for progesterone and androgen receptors, 325
bleeding pattern, 207
clearance after removal of implants, 509
clinical experience, 429
clinical trial, 659
discontinuations, 207
effect on coagulation parameters, 313, 441
effect on estradiol level, 465
effect on metabolic functions, 79, 453
evaluation of acceptability, side effects and effectiveness, 641
regional variations in bleeding patterns, 227
subject characteristics in relation to bleeding patterns, 243
Levonorgestrel-releasing intracervical device,
bleeding pattern, 333
effect on body iron stores, 333

Levonorgestrel-releasing vaginal ring,
analysis of vaginal bleeding patterns, 181
bleeding pattern, 207
discontinuations, 207
regional variations in bleeding patterns, 227
subject characteristics in relation to bleeding patterns, 243
LH (luteinizing hormone)
LH level,
effect of ethinylestradiol + desogestrel, 593
effect of ethinylestradiol + gestodene, 593
Life-style habits, effect on oral contraceptive use, 69
Lipid and lipoprotein changes, during the seven days off oral contraceptive, 19
Lipid and lipoprotein levels,
effect of CuT220c, 605
effect of ethinylestradiol + cyproterone acetate, 419
effect of ethinyl estradiol + levonorgestrel, 605
effect of ethinylestradiol + norethindrone, 19
effect of ethinyl estradiol + norethisterone acetate, 605
effect of ethinylestradiol + dl-norgestrel, 19
Lipid metabolism, effect of levonorgestrel, 79, 453
Lippes loop, consequences of uterine blood loss, 1
Liver function, effect of levonorgestrel, 79, 453
Menstrual bleeding patterns,
analysis, 129
analysis in women using contraception, 181
effect of depot-medroxyprogesterone acetate, 697
effect of norethisterone enanthate, 697
influence of characteristics of contraceptive users, 243
regional variations in contraceptive users, 227
relationship to reasons for discontinuation of contraceptive use, 207
Menstrual blood loss, effect of IUD use, 1
Menstrual cycle, analysis, 129
Menstrual diary card, 129
Menstrual diary system, microcomputer software for analysis of menstrual diaries, 157
Menstrual induction, effect of RU 486, 401
Menstrual pattern, effect of levonorgestrel, 429, 659
Mestranol + ethynodiol diacetate, relative risk of pre-menopausal breast cancer in nulliparous women, 287
Metabolic functions, effect of levonorgestrel, 453
dl-15-Methyl-prostaglandin-$F_{2\alpha}$-methyl ester + RU 486, use in pregnancy interruption, 675
Microcomputer software for analysis of menstrual diaries, 157
Mifepristone (RU 486), ripening effect on cervix, 301
Monoclonal antibody against progesterone, effect on pregnancy (rat), 109
Motility of spermatozoa, effect of copper and copper ions, 685

MSGB (2'-carbomethoxyphenyl 4-guanidinobenzoate)
Multiload-250, consequences of uterine blood loss, 1
Multiload-375, consequences of uterine blood loss, 1
Multiload Cu 375, clinical trial, 631
Na^+,K^+ ATPase activity, effect of gossypol, 579
Natural family planning,
  ovulation prediction with use of CUE™ Monitor, 407
  use of Ovulation Method during breastfeeding, 499
Norethisterone, binding affinity for progesterone and androgen receptors, 325
Norethisterone acetate,
  analysis of vaginal bleeding patterns, 181
  bleeding pattern, 207
  discontinuations, 207
  regional variations in bleeding patterns, 227
  subject characteristics in relation to bleeding patterns, 243
Norethisterone enanthate, acceptability, 697
Norplant®,
  acceptability, side effects and effectiveness, 641
  clearance of levonorgestrel after removal, 509
  effect on coagulation parameters, 313
  effect on estradiol level, 465
  effect on metabolic functions, 79
Norplant®-2,
  acceptability, side effects and effectiveness, 641
  clinical experience, 429
  clinical trial, 659
  effect on coagulation parameters, 441
  effect on metabolic functions, 453
Nulliparous women, oral contraceptives and premenopausal breast cancer, 287
Oestrogen excretion level, post-tubal sterilization, 541
Oral contraceptive,
  ethinylestradiol + cyproterone acetate, 419
  ethinylestradiol + desogestrel, 381, 593
  ethinyl estradiol + ethynodiol diacetate, 287
  ethinylestradiol + gestodene, 477, 593
  ethinyl estradiol + levonorgestrel, 27, 181, 207, 227, 243, 567, 573, 605
  ethinylestradiol + norethindrone, 19, 525
  ethinyl estradiol + norethisterone acetate, 181, 207, 227, 243, 605
  ethinyl estradiol + d-norgestrel, 91
  ethinylestradiol + dl-norgestrel, 19
  levonorgestrel, 181, 207, 227, 243
  mestranol + ethynodiol diacetate, 287
  norethisterone acetate, 181, 207, 227, 243
Oral contraceptive use,
  effect of sexual and reproductive life events, 69
  lipid and lipoprotein changes during the seven pill-free days, 19

Oral contraceptives,
effect on immune system, 567, 573
survey of prescribing habits for high-estrogen pills, 561
Oral contraceptives and premenopausal breast cancer in nulliparous women, 287
Ovarian steroidogenesis, correlated with post-tubal sterilization problems, 541
Ovulation, effect of breastfeeding, 53
Ovulation Method,
analysis of vaginal bleeding patterns, 181
discontinuations, 207
regional variations in bleeding patterns, 227
subject characteristics in relation to bleeding patterns, 243
use-effectiveness during postpartum breastfeeding, 499
Ovulation predictor, use of CUE™ Monitor, 407
Personality profiles, correlation to contraceptive use, 551
Phosphofructokinase activity, effect of ethinyl estradiol + d-norgestrel, 91
Platelet count, effect of levonorgestrel, 641
Platelet function, effect of levonorgestrel, 313, 441
Polymeric device for releasing MSGB, development, 349
Post-tubal sterilization, problems correlated with ovarian steroidogenesis, 541
Pregnancy,
effect of monoclonal antibody against progesterone (rat), 109
effect of zoapatle (rabbit), 373
following microsurgical reversal of female mechanical sterilization, 99
probability in full nursing women, 53
Pregnancy rate, use of Ovulation Method during breastfeeding, 499
Pregnanediol excretion level, post-tubal sterilization, 541
Preimplantation development, effect of RU 486 (mouse), 365
Premenopausal breast cancer and oral contraceptive use, 287
Prescribing habits, high-estrogen contraceptives, 561
Progestational compounds, relative binding affinities for progesterone and androgen receptors, 325
Progesterone level,
effect of ethinylestradiol + desogestrel, 593
effect of ethinylestradiol + gestodene, 593
effect of RU 486, 391, 401
Progesterone level during pregnancy, effect of zoapatle (rabbit), 373
Progesterone receptor binding, progestational compounds, 325
Progesterone-releasing IUD, consequences of uterine blood loss, 1
Prolactin level,
effect of ethinylestradiol + desogestrel, 593
effect of ethinylestradiol + gestodene, 593
fully nursing women, 53

Prostaglandin, dl-15-methyl-prostaglandin-$F_{2\alpha}$-methyl ester, 675
Reanastomosis following female mechanical sterilization, 99
Recovery of ovulation and fertility and lactational amenorrhea, 53
Reference period method,
  analysis of menstrual bleeding patterns, 129
  microcomputer software for analysis of menstrual diaries, 157
Regional variations, menstrual bleeding patterns in contraceptive users, 227
Removal of levonorgestrel implants, clearance of levonorgestrel, 509
Reproductive life events, effect on oral contraceptive use, 69
Reversal of female mechanical sterilization, 99
RU 486 (Mifepristone),
  effect as abortifacient, 391
  effect on cervix, 301
  effect on endometrium, 401
  effect on induction of menstruation, 401
  effect on preimplantation development (mouse), 365
RU 486 + dl-15-methyl-prostaglandin-$F_{2\alpha}$-methyl ester, use in pregnancy interruption, 675
Salivary electrical resistance patterns, temporal relationship to ovulation, 407
Sexual habits, effect on oral contraceptive use, 69
SHBG (sex hormone binding globulin)
SHBG levels,
  effect of ethinylestradiol + cyproterone acetate, 419
  effect of ethinylestradiol + desogestrel, 381, 593
  effect of ethinylestradiol + gestodene, 477, 593
Side effects,
  use of depot-medroxyprogesterone acetate, 697
  use of ethinyl estradiol + norethindrone, 525
  use of levonorgestrel, 429, 641
  use of norethisterone enanthate, 697
  use of RU 486, 391
  use of RU 486 + dl-15-methyl-prostaglandin-$F_{2\alpha}$-methyl ester, 675
Socioeconomic factors, correlation to contraceptive use, 551
Spermatozoa, effect of copper and copper ions, 685
Spermicidal effect, copper and copper ions, 685
Statistical analysis of vaginal bleeding patterns, bibliography, 259
Sterilization, microsurgical reversal, female, 99
T-Chloroquin, consequences of uterine blood loss, 1
TCu 200, consequences of uterine blood loss, 1
TCu 380Ag, clinical trial, 631
Termination of early pregnancy,
  use of RU 486, 301, 391
  use of RU 486 + dl-15-methyl-prostaglandin-$F_{2\alpha}$-methyl ester, 675

Testosterone level,
effect of ethinylestradiol + desogestrel, 593
effect of ethinylestradiol + gestodene, 593
Time-series analysis, use in analysis of menstrual bleeding patterns, 129
Triphasic oral contraceptives containing ethinyl estradiol + norgestrel, summary of data in literature on carbohydrate metabolism, 27
Tubal sterilization, problems correlated with ovarian steroidogenesis after procedure, 541
Ultrastructural study of endometrium, effect of ethinylestradiol, 711
Use-effectiveness, Ovulation Method during postpartum breastfeeding, 499
User satisfaction, Norplant®-2 rods, 429
Vaginal bleeding patterns,
analysis in women using contraception, 181
assessing changes during contraceptive use, 165
bibliography of statistical analysis, 259
relationship to reasons for discontinuation of contraceptive use, 207
Vaginal electrical resistance patterns, temporal relationship to ovulation, 407
Vaginal ring, releasing levonorgestrel, 181, 207, 227, 243
Weight,
effect of depot-medroxyprogesterone acetate, 697
effect of norethisterone enanthate, 697
Zoapatle, effect during pregnancy on progesterone level (rabbit), 373